MX2020006192A - Un conjugado de un analogo de tubulisina con enlazadores ramificados. - Google Patents

Un conjugado de un analogo de tubulisina con enlazadores ramificados.

Info

Publication number
MX2020006192A
MX2020006192A MX2020006192A MX2020006192A MX2020006192A MX 2020006192 A MX2020006192 A MX 2020006192A MX 2020006192 A MX2020006192 A MX 2020006192A MX 2020006192 A MX2020006192 A MX 2020006192A MX 2020006192 A MX2020006192 A MX 2020006192A
Authority
MX
Mexico
Prior art keywords
conjugate
tubulysin analog
branched
branched linkers
conjugation
Prior art date
Application number
MX2020006192A
Other languages
English (en)
Inventor
Yuanyuan Huang
Qingliang Yang
Shun Gai
Hangbo Ye
Huihui Guo
Xiaomai Zhou
Hongsheng Xie
Qianqian Tong
Linyao Zhao
Junxiang Jia
Wenjun Li
Yifang Xu
Lu Bai
Robert Yongxin Zhao
Xiang Cai
Jun Zheng
Jun Lei
Mingjun Cao
Xiaotao Zhuo
Xiuzheng Zhang
Original Assignee
Hangzhou Dac Biotech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hangzhou Dac Biotech Co Ltd filed Critical Hangzhou Dac Biotech Co Ltd
Publication of MX2020006192A publication Critical patent/MX2020006192A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic

Abstract

La presente invención hace referencia a la conjugación de un compuesto análogo de tubulisina con una molécula de unión a células con enlazadores de cadena ramificada/lateral para tener mejor administración del compuesto conjugado y el tratamiento dirigido de células anómalas. También hace referencia a un método de enlace ramificado de conjugación de una molécula de análogo de tubulisina a un ligando de unión a células, así como a métodos para usar el conjugado en el tratamiento dirigido de cáncer, infecciones y enfermedades autoinmunitarias.
MX2020006192A 2017-12-31 2017-12-31 Un conjugado de un analogo de tubulisina con enlazadores ramificados. MX2020006192A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2017/120454 WO2019127607A1 (en) 2017-12-31 2017-12-31 A conjugate of a tubulysin analog with branched linkers

Publications (1)

Publication Number Publication Date
MX2020006192A true MX2020006192A (es) 2020-08-20

Family

ID=67064953

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020006192A MX2020006192A (es) 2017-12-31 2017-12-31 Un conjugado de un analogo de tubulisina con enlazadores ramificados.

Country Status (17)

Country Link
US (4) US20200276261A1 (es)
EP (1) EP3621652A4 (es)
JP (2) JP7262817B2 (es)
KR (2) KR102641565B1 (es)
CN (1) CN111093707A (es)
AU (2) AU2017445144A1 (es)
BR (1) BR112020010405A2 (es)
CA (1) CA3085634C (es)
CL (1) CL2020001600A1 (es)
EA (1) EA202091217A1 (es)
IL (1) IL275274A (es)
MX (1) MX2020006192A (es)
NZ (1) NZ764814A (es)
PH (1) PH12020550657A1 (es)
SG (1) SG11202004801WA (es)
WO (1) WO2019127607A1 (es)
ZA (1) ZA202003211B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2878733C (en) 2012-07-12 2021-09-14 Hangzhou Dac Biotech Co., Ltd Conjugates of cell binding molecules with cytotoxic agents
US11873281B2 (en) 2012-07-12 2024-01-16 Hangzhou Dac Biotech Co., Ltd. Conjugates of cell binding molecules with cytotoxic agents
WO2018156180A1 (en) 2017-02-24 2018-08-30 Kindred Biosciences, Inc. Anti-il31 antibodies for veterinary use
CA3144784A1 (en) * 2019-06-24 2020-12-30 Hangzhou Dac Biotech Co., Ltd A conjugate of a cytotoxic agent to a cell binding molecule with branched linkers
AU2020301115A1 (en) * 2019-06-24 2022-02-10 Hangzhou Dac Biotech Co., Ltd A formulation of a conjugate of a tubulysin analog to a cell-binding molecule
EP3991752A4 (en) * 2019-06-29 2023-03-29 Hangzhou Dac Biotech Co., Ltd CELL BINDING MOLECULE-TUBULYSIN DERIVATIVE CONJUGATE AND METHOD OF PREPARATION THEREOF
WO2021022678A1 (zh) * 2019-08-07 2021-02-11 烟台迈百瑞国际生物医药股份有限公司 一种抗体药物偶联物及其应用
EP3862023A1 (en) * 2020-02-05 2021-08-11 Hangzhou DAC Biotech Co, Ltd Conjugates of cell-binding molecules with cytotoxic agents
US11045546B1 (en) 2020-03-30 2021-06-29 Cytodyn Inc. Methods of treating coronavirus infection
CN112138170B (zh) * 2020-09-28 2022-05-20 广东药科大学 一种预防顺铂药源性聋的缀合物及其制备方法和应用
CN112755173B (zh) * 2020-12-31 2022-01-07 深圳市科达顺生物技术有限公司 用于治疗三阴性乳腺癌的Ii-Key/HER2杂交多肽药物及其制备方法
CN112961060B (zh) * 2021-02-09 2022-03-25 武汉大学 同位素标记的n,n-二甲基乙二胺及其制备方法和短链脂肪酸的分析方法
CN117177775A (zh) * 2021-04-14 2023-12-05 启德医药科技（苏州）有限公司 连接子、缀合物及其应用
EP4355366A1 (en) * 2021-06-16 2024-04-24 Fusion Pharmaceuticals Inc. Combination comprising a neurotensin receptor binding compound and napoli
WO2022078524A2 (en) * 2021-11-03 2022-04-21 Hangzhou Dac Biotech Co., Ltd. Specific conjugation of an antibody
WO2023209625A1 (en) * 2022-04-28 2023-11-02 Scirosbio (Fzc) Compositions and methods for treatment of cancer
WO2023244803A1 (en) * 2022-06-17 2023-12-21 The Regents Of The University Of California Methods and compositions comprising tobacco mild green mosaic virus (tmgmv)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1521769B1 (de) * 2002-07-09 2015-09-09 Dömling, Alexander Tubulysinkonjugate
EP2481427A1 (en) * 2007-03-14 2012-08-01 Endocyte, Inc. Folate-Tubulysin conjugates
US10131682B2 (en) * 2012-11-24 2018-11-20 Hangzhou Dac Biotech Co., Ltd. Hydrophilic linkers and their uses for conjugation of drugs to a cell binding molecules
US10464955B2 (en) * 2014-02-28 2019-11-05 Hangzhou Dac Biotech Co., Ltd. Charged linkers and their uses for conjugation
NZ725131A (en) * 2014-04-11 2018-03-23 Medimmune Llc Tubulysin derivatives
CN110279872A (zh) * 2014-11-11 2019-09-27 杭州多禧生物科技有限公司 细胞毒素分子同细胞结合受体分子的共轭体
NZ737471A (en) * 2015-06-15 2022-02-25 Hangzhou Dac Biotech Co Ltd Hydrophilic linkers for conjugation
CN108289964B (zh) * 2015-08-10 2022-08-12 杭州多禧生物科技有限公司 新型连接体及其用于药物和生物分子的特异性偶联
WO2016059622A2 (en) * 2016-02-04 2016-04-21 Suzhou M-Conj Biotech Co., Ltd. Specific conjugation linkers, specific immunoconjugates thereof, methods of making and uses such conjugates thereof
MX2018012803A (es) * 2016-04-20 2019-06-24 Hangzhou Dac Biotech Co Ltd Derivados de las toxinas de amanita y su conjugacion a una molecula de union celular.
NZ752394A (en) * 2016-11-14 2021-07-30 Hangzhou Dac Biotech Co Ltd Conjugation linkers, cell binding molecule-drug conjugates containing the likers, methods of making and uses such conjugates with the linkers
NZ757008A (en) * 2017-04-06 2022-04-29 Hangzhou Dac Biotech Co Ltd Conjugation of a cytotoxic drug with bis-linkage

Also Published As

Publication number Publication date
KR102641565B1 (ko) 2024-02-27
NZ764814A (en) 2024-02-23
US20230165930A1 (en) 2023-06-01
JP2023093531A (ja) 2023-07-04
AU2017445144A1 (en) 2020-06-18
KR20200097295A (ko) 2020-08-18
BR112020010405A2 (pt) 2020-11-24
CL2020001600A1 (es) 2021-03-19
KR20230075530A (ko) 2023-05-31
WO2019127607A1 (en) 2019-07-04
US20230165931A1 (en) 2023-06-01
EP3621652A1 (en) 2020-03-18
CA3085634A1 (en) 2019-07-04
CA3085634C (en) 2023-11-14
IL275274A (en) 2020-07-30
JP2021507928A (ja) 2021-02-25
PH12020550657A1 (en) 2021-04-19
EA202091217A1 (ru) 2020-09-18
AU2022205269A1 (en) 2022-08-11
SG11202004801WA (en) 2020-06-29
US20230149502A1 (en) 2023-05-18
US20200276261A1 (en) 2020-09-03
JP7262817B2 (ja) 2023-04-24
CN111093707A (zh) 2020-05-01
EP3621652A4 (en) 2021-01-13
KR102603344B1 (ko) 2023-11-16
ZA202003211B (en) 2024-04-24

Similar Documents

Publication Publication Date Title
ZA202003211B (en) A conjugate of a tubulysin analog with branched linkers
PH12019502278A1 (en) Conjugation of a cytotoxic drug with bis-linkage
MX2021015887A (es) Un conjugado de un agente citotóxico y una molécula de unión a células con enlazadores ramificados.
MX2021009147A (es) Un conjugado de un analogo de amatoxina con enlazadores ramificados.
MX2019010804A (es) Compuestos de benzazepina, conjugados y usos de los mismos.
MX2019005617A (es) Linfocitos infiltrantes de tumores remanentes y metodos de preparacion y uso de los mismos.
EA201590622A1 (ru) Конъюгаты для доставки лекарственного средства, содержащие не встречающиеся в природе аминокислоты, и способы применения
NZ737757A (en) Peptide oligonucleotide conjugates
MX2019001302A (es) Conjugados de farmaco con enlazadores autoestabilizantes que tienen propiedades fisioquimicas mejoradas.
PH12015501092A1 (en) Anti-ceacam5 antibodies and uses thereof
NZ708727A (en) Conjugate compounds
MX2023002599A (es) Conjugados de compuestos de tubulisina cuaternizada.
EA201201400A1 (ru) Композиции и способы лечения аутоиммунных и других заболеваний
MX2019012464A (es) Terapia combinada con un conjugado de anticuerpo y farmaco anti-axl.
WO2011103567A3 (en) Peptides and methods for inducing cell death
MX2021015533A (es) Anticuerpos anti-mesotelina e inmunoconjugados de los mismos.
ZA202203201B (en) Therapeutic conjugates
MX2021003184A (es) Hidrogeles de acido hialuronico degradables.
CY1123818T1 (el) Syd985 θεραπεια δυσιατων me t-dm1 ασθενων με καρκινο
MX2020003089A (es) Analogos de tailanstatina.
MX2020002802A (es) Anticuerpos de cadena pesada que se unen a ectoenzimas.
MX2021001545A (es) Péptidos penetrantes celulares.
EA202190457A1 (ru) Конъюгаты для применения в способах лечения рака
MX2021003186A (es) Nuevos conjugados de hidrogel.
PH12016502042A1 (en) Drug delivery conjugates for treating resistant cancer and for use in combination therapy